1. Home
  2. MATV vs ASMB Comparison

MATV vs ASMB Comparison

Compare MATV & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mativ Holdings Inc.

MATV

Mativ Holdings Inc.

HOLD

Current Price

$9.34

Market Cap

494.1M

ML Signal

HOLD

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$30.39

Market Cap

442.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MATV
ASMB
Founded
1995
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Paper
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
494.1M
442.9M
IPO Year
1996
2010

Fundamental Metrics

Financial Performance
Metric
MATV
ASMB
Price
$9.34
$30.39
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$44.20
AVG Volume (30 Days)
325.7K
125.5K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
4.24%
N/A
EPS Growth
N/A
91.78
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$2.97
N/A
Revenue Next Year
$4.20
$638.39
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.46
$13.13
52 Week High
$15.48
$39.71

Technical Indicators

Market Signals
Indicator
MATV
ASMB
Relative Strength Index (RSI) 50.37 57.87
Support Level $8.02 $26.50
Resistance Level $9.99 $30.58
Average True Range (ATR) 0.42 1.55
MACD -0.00 0.36
Stochastic Oscillator 60.86 71.79

Price Performance

Historical Comparison
MATV
ASMB

About MATV Mativ Holdings Inc.

Mativ Holdings Inc is a leader in specialty materials, solving its customers' complex challenges by engineering bold, inventive solutions that connect, protect, and purify the world. The company operates in two segments, namely Filtration & advanced Materials, focused on filtration media and components, developed films, coating and converting solutions, and extruded mesh products, and (2) Sustainable & Adhesive Solutions (SAS), focused on tapes, labels, liners, specialty paper, packaging, and healthcare solutions.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

Share on Social Networks: